Drew Ranieri
Stock Analyst at Morgan Stanley
(1.22)
# 3,699
Out of 5,090 analysts
170
Total ratings
44.57%
Success rate
-11.43%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SIBN SI-BONE | Maintains: Overweight | $20 → $23 | $19.68 | +16.87% | 16 | Dec 2, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $70 → $100 | $91.10 | +9.77% | 14 | Dec 2, 2025 | |
| ATEC Alphatec Holdings | Maintains: Equal-Weight | $16 → $21 | $21.45 | -2.10% | 11 | Nov 10, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.74 | +26.58% | 4 | Mar 5, 2025 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $364.02 | +22.25% | 9 | Dec 2, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $13.23 | +104.08% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $2.74 | +191.97% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $22.11 | -0.50% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $16.40 | -51.22% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $4.39 | +1,779.27% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.23 | +87.84% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $83.94 | +14.37% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.26 | +130.91% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $193.96 | +52.09% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $120.50 | +132.37% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $7.09 | -29.48% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $18.54 | +277.56% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $575.34 | -47.86% | 6 | Apr 25, 2022 |
SI-BONE
Dec 2, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $19.68
Upside: +16.87%
Globus Medical
Dec 2, 2025
Maintains: Overweight
Price Target: $70 → $100
Current: $91.10
Upside: +9.77%
Alphatec Holdings
Nov 10, 2025
Maintains: Equal-Weight
Price Target: $16 → $21
Current: $21.45
Upside: -2.10%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.74
Upside: +26.58%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $364.02
Upside: +22.25%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $13.23
Upside: +104.08%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $2.74
Upside: +191.97%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $22.11
Upside: -0.50%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $16.40
Upside: -51.22%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $4.39
Upside: +1,779.27%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.23
Upside: +87.84%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $83.94
Upside: +14.37%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.26
Upside: +130.91%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $193.96
Upside: +52.09%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $120.50
Upside: +132.37%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $7.09
Upside: -29.48%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $18.54
Upside: +277.56%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $575.34
Upside: -47.86%